SynBioBeta Speaker
Kevin Flyangolts
Aclid
CEO
Kevin Flyangolts is the Founder and CEO of Aclid, the leading platform for biosecurity and biosafety. Aclid's compliance automation and biological threat monitoring support responsible innovation in the life sciences and safeguard the bioeconomy. At the intersection of AI and biology, Aclid has been at the forefront of defending against new biosecurity vulnerabilities from advances in AI and protein design.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Kevin
This Year
•
-
Business of Biology
The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology
As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.
Purchase Pass
•
-
Business of Biology
The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology
As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.
Purchase Pass
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
